



## **IBA Expands International Customer Base with Two New Major RadioPharmacy Contracts**

***Placement of two new IntegraLab® - Cyclone® 18, the integrated radiopharmacy solution for medical radioisotope production***

**Louvain-La-Neuve, Belgium, June 05, 2012** - IBA (Ion Beam Applications S.A.), the global high-tech leader in the development of next generation proton therapy technologies and radiopharmaceuticals for targeted cancer diagnosis and therapy, is pleased to announce that it has signed two new contracts to supply IBA's unique IntegraLab® - Cyclone® 18, an integrated radiopharmacy solution for medical radioisotope production. The value of the two contracts is worth at least €5 million in revenue to IBA.

The contracts are an example of IBA's new streamlined approach to utilizing its unique expertise in the field of radioisotope production to provide more integrated solutions to customers, which not only includes equipment, but also a tailored approach to high quality service. This ensures each customer is provided with the most state of the art equipment and services for the establishment of radiopharmaceutical production centers, whilst achieving full regulatory compliance.

The new international contracts are as follows:

- **Amman, Jordan** for the implementation of an IntegraLab® solution at the Afia Radiotherapy and Nuclear Medicine Center. IBA will deliver the center design, Synthera® modules, radiopharmacy equipment for 18F-FDG (Fluorodeoxyglucose) production and the Cyclone® 18 Twin.
- **Krasnoyarsk, Russia**, the contract covers an IntegraLab® solution including the Cyclone® 18 the Synthera® modules, the related radiopharmacy equipment and consultancy to make the centre ready to be fully compliant. This contract strengthens the presence of IBA within the Russian Federation.

**Olivier Legrain, Chief Executive Officer of IBA commented:** "These new relationships demonstrate our international reach and the demand for our unique IntegraLab® solutions. Acquiring a cyclotron is only the first step in a complex project of acquiring a fully functional radiopharmacy capability, one that requires all components and auxiliary equipment to be integrated into a consistent and efficient IBA solution. In these cases, customers require the world leading support and expertise that only IBA can provide.

"The fresh revenue helps us on our journey at IBA to growing a sustainable multinational business. The new customers are an endorsement of our high-end medical equipment which we believe provides a highly effective radiopharmacy solution for nuclear medicine departments in hospitals."

IBA is exhibiting at booth number #709 at the Society for Nuclear Medicine (SNM) Annual Meeting 2012 from 9-13 June in Miami, Florida. For further information please visit: <http://www.iba-snm2012.com/booth-activities>



## Press release |

### **About IntegraLab® and Synthera®**

IntegraLab® is a fully integrated radiopharmacy solution combining equipment and services for the establishment of radiopharmaceutical production centers. IntegraLab® includes among others, the building design achieving full regulatory compliance and the selection, integration, supply and installation of suitable equipment to match the customer's radioisotopes production goals.

Synthera® is a multi-purpose automated synthesizer for the production of 18F-FDG, other 18F-labeled compounds (18FCH, 18FLT, Na18F). Synthera® is designed to accommodate a wide range of radiochemistries.

### **About IBA**

IBA (Ion Beam Applications S.A.), is a cancer diagnostics and treatment company and the worldwide technology leader in the field of proton therapy. The Company's expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment including IBA's leading fully integrated IntegraLab® radiopharmacy system.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange Euronext. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)

### **For further information please contact:**

#### **IBA**

Thomas Ralet

+32 10 475 890

[Thomas.Ralet@iba-group.com](mailto:Thomas.Ralet@iba-group.com)

### **For media and investor enquiries:**

#### **M:Communications**

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson

+44 (0) 207 920 2333

[IBA@mcomgroup.com](mailto:IBA@mcomgroup.com)